Ocugen

Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").

eye-5248678

News

OCGN

Ocugen shares are trading lower by 11% Thursday morning. The company announced the pricing of its public offering.

Why Ocugen (OCGN) Stock Is Falling

movers

Pre-Market Outlook

Markets

Movers

Trading Ideas

ARQT

QGEN

SEDG

VNDA

Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday&#39;s Pre-Market Session

xr:d:DAFjWRRL4Oc:2,j:5026988134,t:23051909

ASTS

CBRL

ERAS

TELL

TTWO

DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Ocugen Inc

Health Care

Press Releases

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19

Biotech

General

Ocugen Announces Positive Opinion of European Medicines Agency's Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa

Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Legal

Grabar Law Office Is Investigating Claims On Behalf Of Long-Term Shareholders Of Atkore Inc. (NYSE: ATKR); Crocs, Inc. (NASDAQ: CROX); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease

Grabar Law Office is Investigating Claims on Behalf of Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); and Ocugen, Inc. (NASDAQ: OCGN)

Ocugen Announces Positive Opinion of EMA's Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

Earnings

Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results

ATKR

CROX

DRVN

MRCY

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Cargo Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nuvectis Pharma

Puma Biotechnology

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

RAPT Therapeutics

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Tiziana Life Sciences Ltd - Common Shares

Tiziana Life Sciences

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

2seventy bio

Chardan Capital

HC Wainwright & Co.

Maxim Group

Cantor Fitzgerald

Mizuho

Comments

Ocugen

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga